The Bipolar Depression Market is growing at a Significant CAGR Driven by the Potential Pipeline Therapies | DelveInsight

DelveInsight's Bipolar Depression market report provides thorough comprehension of Bipolar Depression, historical and forecasted epidemiology, and Bipolar Depression market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan).

As per DelveInsight analysis, the Bipolar Depression market will experience a significant impact in the coming years owing to the increase in awareness and technology, advancement towards precision medicine, expected launch of emerging drugs, entry of emerging drugs from key Bipolar Depression companies such as COMPASS Pathways, Celon Pharma, NeuroRx, and others.

Bipolar Depression Overview

Bipolar Disorder is a mental disorder marked by mood swings between depression and mania. Bipolar Depression is classified into four types based on the characteristics of the episodes: BD-I, BD-II, cyclothymic disorder, and bipolar disorder not otherwise specified. The Bipolar Depression symptoms can differ. Patients may experience manic, depressive, or mixed episodes. Mixed episodes have characteristics of both manic and depressive episodes and can last a week or longer. If these episodes are not treated, the duration and frequency of these episodes may decrease. Bipolar Depression diagnosis is very difficult, and it is frequently mistaken for unipolar depression. A physical examination, psychiatric evaluation, mood charting, and the application of DSM-5 criteria for bipolar episodes are usually required for the Bipolar Depression diagnosis.

Download Sample Report- https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Regions covered in the report

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Key Takeaways from the Bipolar Depression Market Report

• DelveInsight's analysts estimate that the Bipolar Depression market is anticipated to show positive growth during the forecast period.
• As per DelveInsight estimates, the total Bipolar Depression diagnosed prevalent cases were approx. 2.4 million in the US in 2020, which is further expected to increase by 2032.
• As per the estimates, the highest Bipolar Depression prevalent cases were of severe bipolar depression cases followed by moderate and mild in the UK in 2020.
• The leading Bipolar Depression companies such as Intra-Cellular Therapies, NeuroRx, Otsuka, Lundbeck, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, Celon Pharma, and others are developing therapies that are expected to launch their drugs in the Bipolar Depression market
• Key Bipolar Depression therapies in the pipeline include Caplyta (Lumateperone; ITI-007), NRX-100/NRX-101, Rexulti/Rxulti (Brexpiprazole), SEP-4199, COMP 360 (Psilocybin Therapy), Falkieri (Esketamine DPI) are expected to bring the positive shift in the market along with others.
Bipolar Depression Epidemiology Segmentation in the 7MM

The Bipolar Depression report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
• Bipolar Depression Total Diagnosed Prevalent Cases
• Bipolar Depression Type-Specific Diagnosed Prevalent Cases
• Bipolar Depression Severity-Specific Diagnosed Prevalent Cases
• Bipolar Depression Total Treated Cases

Bipolar Depression Treatment Market

Bipolar Depression treatment's ultimate goal is to achieve a high level of psychosocial function and health-related quality of life. Bipolar Depression is a highly recurrent disorder, and sometimes medication needs to continue even if the patient feels well. For bipolar depression patients, several off-label uses of therapies, or combinatorial therapy, are common. Anticonvulsants (such as Divalproex and Lamotrigine), Olanzapine monotherapy, and combined lithium and lamotrigine therapy have all been shown to reduce the severity of depressive symptoms in Bipolar Depression patients. Except for fluoxetine when combined with olanzapine, no antidepressant is explicitly approved by the FDA for bipolar depression treatment.

Bipolar Depression Market Outlook

Antidepressant monotherapy is discouraged in bipolar I disorder, mainly when mixed features are present and even when combined with a mood stabilizer. ECT, repetitive transcranial magnetic stimulation, deep brain stimulation, vagus nerve stimulation, lifestyle interventions, and psychotherapies are examples of non-pharmacological treatment for bipolar depression. ECT is commonly used for treatment-refractory depression. Psychotherapy, such as psychoeducation, CBT, family-focused therapy, dialectical behavior therapy, mindfulness-based CBT, and interpersonal and social rhythm therapy, is useful primarily as adjunctive treatments for managing bipolar depression.

As of now, only four bipolar depression medications have received FDA approval for acute bipolar depression and are available in the bipolar depression market. The olanzapine‐fluoxetine combination (OFC) was first approved in 2003. Quetiapine was approved in 2006. In 2013, lurasidone was approved as a monotherapy and adjunct to ongoing lithium or valproate for bipolar I depression. The fourth, cariprazine, was approved in 2019. Moreover, a robust pipeline in the Bipolar Depression treatment landscape is indicative of the very high bipolar depression market potential of drugs, this includes Caplyta, NRX-100/NRX-101, Rexulti/Rxulti, SEP-4199, COMP 360, Falkieri, and others.

Do you know market size of the report? - https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Bipolar Depression Pipeline Therapies and Key Companies

• Caplyta (Lumateperone; ITI-007): Intra-Cellular Therapies
• NRX-100/NRX-101: NeuroRx
• Rexulti/Rxulti (Brexpiprazole): Otsuka/ Lundbeck
• SEP-4199: Sunovion (Sumitomo Dainippon Pharma)
• COMP 360 (Psilocybin Therapy): COMPASS Pathways
• Falkieri (Esketamine DPI): Celon Pharma

Bipolar Depression Market Dynamics

A robust pipeline of novel and emerging therapies, increase in awareness and technology, advancement towards precision medicine for bipolar depression, future directions in blood biomarkers, and others serve as major aspects for Bipolar Depression market growth in the upcoming years. However, misdiagnosis of bipolar depression, unsatisfactory design of RCTs, limited understanding of the disease mechanism, are among the factors that can affect the Bipolar Depression market growth.

Table of Content

1. Key Insights
2. Executive Summary of Bipolar Depression (Manic Depression)
3. Competitive Intelligence Analysis for Bipolar Depression (Manic Depression)
4. Bipolar Depression Market Overview at a Glance
5. Bipolar Depression (Manic Depression): Disease Background and Overview
6. Patient Journey
7. Bipolar Depression (Manic Depression) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Bipolar Depression Unmet Needs
10. Key Endpoints of Bipolar Depression Treatment
11. Bipolar Depression Marketed Products
12. Bipolar Depression (Manic Depression) Emerging Therapies
13. Bipolar Depression (Manic Depression): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Bipolar Depression Market Outlook
16. Access and Reimbursement Overview of Bipolar Depression (Manic Depression)
17. KOL Views
18. Bipolar Depression Market Drivers
19. Bipolar Depression Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Bipolar Depression Market Report Highlights

• In the coming years, the Bipolar Depression market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Bipolar Depression R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Bipolar Depression. The launch of emerging therapies will significantly impact the Bipolar Depression market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Bipolar Depression
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Why should you buy this report?

• The report will help in developing business strategies by understanding trends shaping and driving the Bipolar Depression market
• To understand the future market competition in the Bipolar Depression market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Bipolar Depression (Manic Depression) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Bipolar Depression market
• To understand the future market competition in the Bipolar Depression market.

Do you have any query related to report? If yes, visit here- https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.